Published in Clin Sci Mol Med Suppl on December 01, 1978
Salbutamol in treatment of heart failure. Br Heart J (1980) 1.27
Correlation between changes in systolic time intervals and left ventricular end-diastolic diameter after preload reduction. Non-invasive monitoring of pharmacological intervention. Br Heart J (1980) 1.10
Ventricular extrasystoles during thiazide treatment. Br Med J (Clin Res Ed) (1983) 0.80
The role of digitalis in the future. Br J Clin Pharmacol (1984) 0.75
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet (1997) 6.48
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
Incidence and aetiology of heart failure; a population-based study. Eur Heart J (1999) 4.56
Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation (2001) 4.32
The epidemiology of heart failure. Eur Heart J (1997) 4.31
Effect of socioeconomic deprivation on waiting time for cardiac surgery: retrospective cohort study. BMJ (2000) 4.21
The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res (1988) 3.98
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet (1993) 3.56
Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J (2001) 3.49
Wasting as independent risk factor for mortality in chronic heart failure. Lancet (1997) 3.37
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06
Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet (1999) 3.01
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. J Am Coll Cardiol (1995) 2.89
Prevalence of heart failure in three general practices in north west London. Br J Gen Pract (1992) 2.88
Survival of patients with a new diagnosis of heart failure: a population based study. Heart (2000) 2.86
Effect of reducing ambulance response times on deaths from out of hospital cardiac arrest: cohort study. BMJ (2001) 2.85
Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation (1997) 2.69
Seasonal variations in coronary heart disease. QJM (1999) 2.65
Heart failure in a district general hospital. J R Coll Physicians Lond (1992) 2.61
Hospitalization of patients with heart failure: a population-based study. Eur Heart J (2002) 2.54
17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation (1995) 2.49
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation (2000) 2.49
The potential impact of patient self-referral on mortality in acute myocardial infarction. Q J Med (1993) 2.43
Relationship between internal calcium and outward current in mammalian ventricular muscle; a mechanism for the control of the action potential duration? J Physiol (1976) 2.32
Pathogenesis of edema in constrictive pericarditis. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones before and after pericardiectomy. Circulation (1991) 2.28
Downregulation of immunodetectable connexin43 and decreased gap junction size in the pathogenesis of chronic hibernation in the human left ventricle. Circulation (1998) 2.26
Hypothesis: inhibition of endothelium-derived relaxing factor by haemoglobin in the pathogenesis of pre-eclampsia. Lancet (1990) 2.24
The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol (1999) 2.18
Performance of an established system of first responder out-of-hospital defibrillation. The results of the second year of the Heartstart Scotland Project in the 'Utstein Style'. Resuscitation (1993) 2.17
Respiratory gas exchange in the assessment of patients with impaired ventricular function. Br Heart J (1985) 2.17
Randomized clinical trial on enhanced recovery versus standard care following open liver resection. Br J Surg (2013) 2.15
Thrombolysis in myocardial infarction. BMJ (1994) 2.13
Six minute walking test for assessing exercise capacity in chronic heart failure. Br Med J (Clin Res Ed) (1986) 2.09
Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol (1997) 2.08
Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol (1997) 2.05
Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation (1993) 2.05
Mechanism of the increased ventilatory response to exercise in patients with chronic heart failure. Br Heart J (1990) 2.00
Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J (1998) 1.97
Hypoxia and calcium. J Mol Cell Cardiol (1979) 1.94
The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J (2004) 1.84
The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J (1997) 1.80
Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation (2001) 1.78
Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol (1996) 1.76
Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int (2002) 1.75
Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation (2001) 1.75
Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. Eur Heart J (2004) 1.74
Serum sickness complicating intravenous streptokinase therapy in acute myocardial infarction. Eur Heart J (1984) 1.72
Value and limitations of adenosine in the diagnosis and treatment of narrow and broad complex tachycardias. Br Heart J (1989) 1.70
First permanent implant of the Jarvik 2000 Heart. Lancet (2000) 1.68
Beta endorphin release in patients after spontaneous and provoked acute myocardial ischaemia. Br Heart J (1992) 1.67
Abnormalities of skeletal muscle in patients with chronic heart failure. Int J Cardiol (1988) 1.66
Sex differences in outcome following community-based cardiopulmonary arrest. Eur Heart J (2000) 1.64
Role of endogenous opioids and catecholamines in vasovagal syncope. Eur Heart J (1996) 1.63
Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol (1997) 1.63
Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol (1993) 1.62
Heart failure: why and how to define it? Eur J Heart Fail (1999) 1.61
Efficacy of out of hospital defibrillation by ambulance technicians using automated external defibrillators. The Heartstart Scotland Project. Resuscitation (1992) 1.60
Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. Am J Cardiol (1991) 1.59
Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J (1993) 1.58
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J (2000) 1.55
Calcium out of control. J Mol Cell Cardiol (1984) 1.55
Pulmonary artery pressure changes during exercise and daily activities in chronic heart failure. J Am Coll Cardiol (1990) 1.53
The time of onset and severity of acidosis in myocardial ischaemia. J Mol Cell Cardiol (1980) 1.50
Is aspirin safe for patients with heart failure? Br Heart J (1995) 1.49
Measurement of cardiac output during exercise by the thermodilution and direct Fick techniques in patients with chronic congestive heart failure. Am J Cardiol (1985) 1.46
Acute hepatitis after parenteral amiodarone administration. Br Heart J (1988) 1.46
Predictors of prognosis in severe chronic heart failure. Am Heart J (1992) 1.46
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J (2001) 1.46
Failure to demonstrate myocardial ischaemia in patients with angina and normal coronary arteries. Evaluation by continuous coronary sinus pH monitoring and lactate metabolism. Eur Heart J (1996) 1.46
Congenital and acquired long QT syndrome. Eur Heart J (2000) 1.45
Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation (1989) 1.44
Reduced anisotropy of action potential conduction in left ventricular hypertrophy. J Cardiovasc Electrophysiol (2001) 1.43
Regulation of ACh release from guinea pig bladder urothelial cells: potential role in bladder filling sensations. Br J Pharmacol (2014) 1.42
Testosterone relaxes rabbit coronary arteries and aorta. Circulation (1995) 1.42
When is it futile for ambulance personnel to initiate cardiopulmonary resuscitation? BMJ (1995) 1.42
Can heart rate variation rule out sleep-disordered breathing in heart failure? Eur Respir J (2006) 1.41
Cardiac pacing. Lancet (1997) 1.41
Treatment of chronic heart failure: a review of recent drug trials. Br Med J (Clin Res Ed) (1985) 1.41
Commentary on "Effects of ischaemia and reperfusion on calcium exchange and mechanical function in isolated rabbit myocardium". Cardiovasc Res (2000) 1.41
Non-invasive assessment of vascular function; paradoxical vascular response to intravenous glucose in coronary heart disease. Eur Heart J (2000) 1.39
Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation (1995) 1.39
Dimensional accuracy of magnetic resonance in studies of the heart. Lancet (1985) 1.37
Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J (1994) 1.37
Purinergic regulation of guinea pig suburothelial myofibroblasts. J Physiol (2004) 1.37
Effect of pH on ionic exchange and function in rat and rabbit myocardium. Am J Physiol (1975) 1.37
Measurement of myocardial intracellular pH in pathological states. J Mol Cell Cardiol (1978) 1.37
Endothelium-independent relaxation of rabbit coronary artery by 17 beta-oestradiol in vitro. Br J Pharmacol (1991) 1.35
Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation (2001) 1.33
Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol (1992) 1.30
Pathogenesis of congestive state in chronic obstructive pulmonary disease. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Circulation (1992) 1.30
Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol (1997) 1.29
ECS, intracellular pH, and electrolytes of cardiac and skeletal muscle. Am J Physiol (1975) 1.27
Salbutamol in treatment of heart failure. Br Heart J (1980) 1.27
The electrophysiological and mechanical effects of 2,3-butane-dione monoxime and cytochalasin-D in the Langendorff perfused rabbit heart. Exp Physiol (2004) 1.25
Oscillatory breathing patterns during wakefulness in patients with chronic heart failure: clinical implications and role of augmented peripheral chemosensitivity. Circulation (1999) 1.25